EMA Recommends Extension of Therapeutic Indications for Retifanlimab By Ogkologos - February 6, 2026 328 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with squamous cell carcinoma of the anal canal Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Cancer in My Community: Caring for Children With Cancer in Paraguay June 8, 2023 Teen Quarterback Scores 8 Touchdowns A Day After His Mom Dies... November 20, 2021 How to Cope With Panic Attacks During Cancer July 12, 2022 Maintenance Rucaparib for Platinum-Sensitive Pancreatic Adenocarcinoma with HRD-Associated Mutations May 17, 2021 Load more HOT NEWS Screen-Detected Colorectal Cancers Have a More Favourable Stage Distribution than Colorectal... ESMO Announces Results of 2025 Elections COVID-19 vaccine and cancer – latest updates Diagnosed With Breast Cancer At 24, Her Biggest Fear Wasn’t Death...
